Related Experiment Video
Updated: Feb 7, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six
G George1, D Enting2, H Garmo1,3
1Transforming cancer OUtcomes through Research (TOUR), School of Cancer and Pharmaceutical Studies, King's College London, London, UK.
Background:
We investigated patterns of gonadotropin-releasing hormone (GnRH) analogue use in castration-resistant prostate cancer (CRPC) using real-world data from six countries.
Patients And Methods:
Data were obtained from Guy's and St Thomas' NHS Foundation Trust (GSTT, UK), Prostate Cancer data Base Sweden (PCBaSe RAPID 2019, Sweden), Système National Des Données De Santé (SNDS, France), European Institute of Oncology (IEO, Italy), Ghent University Hospital (GUH, Belgium), and American University of Beirut Medical Center (AUB, Lebanon). Men diagnosed with CRPC between 2017 and 2019 were included in the study, with data extended to 2020 where available. Cox proportional hazards regression models were used to assess the effect of discontinuing GnRH analogues on overall mortality, adjusting for: age, Charlson Comorbidity Index (CCI), initial prostate cancer (PCa) treatment, and PCa risk group.
Results:
Out of 24 141 men with CRPC across the six countries, 1367 patients discontinued GnRH analogues. The discontinuation rates varied by country, with notable proportions from Sweden (338 men, 13%), France (1024 men, 5%), and Lebanon (5 men, 13%). Following adjustment for age, CCI, initial treatment for PCa, and PCa risk group, a higher risk of mortality in men who discontinued GnRH analogues was observed in Sweden (hazard ratio 2.30, 95% confidence interval 2.03-2.62).
Conclusions:
Our study showed that although guidelines recommend the continued use of GnRH analogues in men with CRPC, a small proportion of men discontinue, the reasons for which are not fully understood. Further research is needed to explore potential contributing factors, such as differences in clinical practices, patient characteristics, or health care system across the countries studied.
Related Concept Videos
02:56Treatment Resistant Cancers
01:14What is Variation?
The range, standard deviation, standard error, and variance are the different measures of variation.
Range: The range is the difference between its maximum and...
02:53Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
01:19Variation
When independent and dependent variables are plotted on a scatter plot, the slope of a line is a value that describes the rate of change between the two...
01:18Variation of Atmospheric Pressure
Assuming the air temperature is constant at a given altitude and that the ideal gas law of thermodynamics describes the atmosphere to a good approximation, one can find the variation of atmospheric pressure with height.
Let p(y) be the atmospheric pressure at...
02:26Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...